Ann Knoop
Overview
Explore the profile of Ann Knoop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lauritzen A, Berg T, Jensen M, Lillholm M, Knoop A
Acta Oncol
. 2023 Apr;
62(4):350-357.
PMID: 37074036
Background: More than 4500 women are diagnosed with breast cancer each year in Denmark, however, despite adequate treatment 10-30% of patients will experience a recurrence. The Danish Breast Cancer Group...
12.
Garly R, Berg T, Jensen M, Knoop A, Volmer L, Glavicic V, et al.
Acta Oncol
. 2023 Apr;
62(3):290-297.
PMID: 37010239
Background: The recommended first-line treatment for advanced, ER+/HER2 negative breast cancer is a CDK 4/6 inhibitor in combination with an endocrine backbone. This study investigated the use of palbociclib, as...
13.
Due A, Berg T, Jensen M, Yammeni S, Volmer L, Brems-Eskildsen A, et al.
Acta Oncol
. 2023 Mar;
62(2):126-133.
PMID: 36929759
Background: Current guidelines in HER2-positive metastatic breast cancer (mBC) recommend the combination of trastuzumab and a chemotherapeutic agent for 3rd line or later treatments. This study aims to describe the...
14.
Hillersdal L, Nielsen Z, Normark A, Knoop A, Piil K
BMC Cancer
. 2022 Oct;
22(1):1097.
PMID: 36289456
Objectives: Existing research on the perspectives of patients with cancer and health care professionals indicates that patient decision making on cancer clinical trial participation is a complex process and may...
15.
Reznitsky F, Jensen J, Knoop A, Laenkholm A
APMIS
. 2022 May;
130(9):545-550.
PMID: 35639634
Tumor infiltrating lymphocytes (TILs) have predictive and prognostic potential in HER2-positive breast cancer (HER2 + BC). Due to tumor heterogeneity, guidelines recommend evaluation on full tumor-sections over biopsies, but aren't...
16.
Celik A, Berg T, Nielsen L, Jensen M, Ejlertsen B, Knoop A, et al.
Breast Cancer (Auckl)
. 2022 Apr;
16:11782234221086992.
PMID: 35359608
Purpose: Dual blockade with trastuzumab and pertuzumab in combination with chemotherapy is the recommended first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). The purpose...
17.
Pappot H, Baeksted C, Nissen A, Knoop A, Mitchell S, Christensen J, et al.
Breast Cancer
. 2021 Apr;
28(5):1096-1099.
PMID: 33837509
The involvement of cancer patients in symptom reporting talks into our cultural narrative of empowerment and participation in decisions in health of both patients and professionals. Electronic patient-reported outcome (ePRO)...
18.
Christensen T, Berg T, Nielsen L, Andersson M, Jensen M, Knoop A
Breast
. 2020 Mar;
51:34-39.
PMID: 32200206
Objectives: Randomized clinical trials do not include a population that truly reflects a real-world population, due to their inclusion and exclusion criteria. This leads to concerns about the applicability of...
19.
Baeksted C, Nissen A, Knoop A, Christiansen M, Pappot H
Breast J
. 2019 Jul;
25(6):1295-1296.
PMID: 31353754
No abstract available.
20.
Pappot H, Baeksted C, Knoop A, Mitchell S, Nissen A, Johansen C
Breast J
. 2019 Feb;
25(2):269-272.
PMID: 30761667
The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The...